Enveda raises $311 million to advance nature-derived AI drugs in clinical trialsMachine translation
Automatically verified and published · Generated and evidence-checked automatically; not reviewed by a human.
Biotech startup Enveda has raised $311 million in a Series E round at a $2 billion valuation. It uses AI to seek drugs from plants and microbes and is testing several candidates in patients, including one targeting severe skin conditions and another designed to help maintain weight loss after stopping GLP-1s.
The complete source text is not yet available.
Read at the original source